A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: A role of inhibitory dopamine d1/5 receptors in the prefrontal cortex?

Neuroscience

Volumn 124, Issue 1, 2004, Pages 33-42

  Isacson, R ^a   Kull, B ^a   Wahlestedt, C ^a   Salmi, P ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

d amphetamine; Dopamine D1 receptor; Immediate early gene; Locomotion; Rat

Indexed keywords

1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DEXAMPHETAMINE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 5 RECEPTOR; NEUROLEPTIC AGENT; PROTEIN C FOS; RACLOPRIDE TARTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOSE RESPONSE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; HABITUATION; HYPERACTIVITY; LOCOMOTION; NEUROMODULATION; NONHUMAN; ONCOGENE C FOS; OPEN FIELD BEHAVIOR; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEREOTYPY;

EID: 0442307957     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2003.11.016     Document Type: Article

References (40)

1. Abrahams B.S., Rutherford J.D., Mallet P.E., Beninger R.J. Place conditioning with the dopamine D1-like receptor agonist SKF 82958 but not SKF 81297 or SKF 77434. Eur J Pharmacol. 343:1998;111-118.
2. AI-Naser H.A., Cooper S.J. A-68930, a novel, potent dopamine D1 receptor agonist a microstructural analysis of its effects on feeding and other behaviour in the rat . Behav Pharmacol. 5:1994;210-218.
3. Beninger R.J. The role of dopamine in locomotor activity and learning. Brain Res. 287:1983;173-196.
4. Campbell A., Villavicencio A.T., Yeghiayan S.K., Balikian R., Baldessarini R.J. Mapping of locomotor behavioral arousal induced by microinjections of dopamine within nucleus accumbens septi of rat forebrain. Brain Res. 771:1997;55-62.
5. Canales J.J., Iversen S.D. Psychomotor-activating effects mediated by dopamine D(2) and D(3) receptors in the nucleus accumbens. Pharmacol Biochem Behav. 67:2000;161-168.
6. Carr D.B., Sesack S.R. Projections from the rat prefrontal cortex to the ventral tegmental area target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons . J Neurosci. 20:2000;3864-3873.
7. Castner S.A., Williams G.V., Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science. 287:2000;2020-2022.
8. Curran T., Gordon M.B., Rubino K.L., Sambucetti L.C. Isolation and characterization of the c-fos(rat) cDNA and analysis of post-translational modification in vitro. Oncogene. 2:1987;79-84.
9. Darney K.J. Jr, Lewis M.H., Brewster W.K., Nichols D.E., Mailman R.B. Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacology. 5:1991;187-195.
10. DeNinno M.P., Schoenleber R., MacKenzie R., Britton D.R., Asin K.E., Briggs C., Trugman J.M., Ackerman M., Artman L., Bednarz L., et al. A68930 a potent agonist selective for the dopamine D1 receptor . Eur J Pharmacol. 199:1991;209-219.
11. Deveney A.M., Waddington J.L. Psychopharmacological distinction between novel full-efficacy "D1-like" dopamine receptor agonists. Pharmacol Biochem Behav. 58:1997;551-558.
12. Ericson E., Samuelsson J., Ahlenius S. Photocell measurements of rat motor activity a contribution to sensitivity and variation in behavioral observations . J Pharmacol Methods. 25:1991;111-122.
13. Glavin G.B. The antisecretory effects of clozapine, a dopamine D4 receptor antagonist, are blocked by the dopamine D1 receptor antagonist, SCH23390. Life Sci. 56:(PL365):1995;368.
14. Jackson D.M., Westlind-Danielsson A. Dopamine receptors molecular biology, biochemistry and behavioural aspects . Pharmacol Ther. 64:1994;291-370.
15. Knable M.B., Weinberger D.R. Limbic-prefrontal connectivity and clozapine. J Clin Psychiatry. 55:(Suppl B):1994;70-73.
16. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol. 11:1997;123-131.
17. Lewis M.H., Baumeister A.A., McCorkle D.L., Mailman R.B. A computer-supported method for analyzing behavioral observations studies with stereotypy . Psychopharmacology (Berl). 85:1985;204-209.
18. Makanjuola R.O., Ashcroft G.W. Behavioural effects of electrolytic and 6-hydroxydopamine lesions of the accumbens and caudate-putamen nuclei. Psychopharmacology (Berl). 76:1982;33-40.
19. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 5:2002;267-271.
20. Meyer M.E., Shults J.M. Dopamine D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats. Pharmacol Biochem Behav. 46:1993;269-274.
21. Mottola D.M., Brewster W.K., Cook L.L., Nichols D.E., Mailman R.B. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther. 262:1992;383-393.
22. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
23. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, 4th ed. 1998;Academic Press, Sydney.
24. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 286:1980;74-76.
25. Radcliffe R.A., Erwin V.G. Alterations in locomotor activity after microinjections of GBR-12909, selective dopamine antagonists or neurotensin into the medial prefrontal cortex. J Pharmacol Exp Ther. 277:1996;1467-1476.
26. Salmi P. Independent roles of dopamine D1 and D2/3 receptors in rat thermoregulation. Brain Res. 781:1998;188-193.
27. 1 receptor agonist. Eur J Pharmacol. 307:1996;27-31.
28. Salmi P., Ahlenius S. Dihydrexidine produces hypothermia in rats via activation of dopamine D1 receptors. Neurosci Lett. 236:1997;57-59.
29. Salmi P., Ahlenius S. Sedative effects of the dopamine D1 receptor agonist A 68930 on rat open-field behavior. Neuroreport. 11:2000;1269-1272.
30. Salmi P., Karlsson T., Ahlenius S. Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. Eur J Pharmacol. 253:1994;67-73.
31. Salmi P., Malmgren K., Svensson T.H., Ahlenius S. Stimulation of forward locomotion by SCH-23390 and raclopride in d-amphetamine-treated rats. Naunyn Schmiedebergs Arch Pharmacol. 357:1998;593-599.
32. Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics an in situ hybridization study . Neurochem Int. 29:1996;435-442.
33. Sesack S.R., Deutch A.Y., Roth R.H., Bunney B.S. Topographical organization of the efferent projections of the medial prefrontal cortex in the rat an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin . J Comp Neurol. 290:1989;213-242.
34. Siegel S., Castellan N.J. Nonparametric statistics for the behavioral sciences. 1988;McGraw-Hill, New York.
35. Thompson T.L., Moss R.L. In vivo stimulated dopamine release in the nucleus accumbens modulation by the prefrontal cortex . Brain Res. 686:1995;93-98.
36. Tzschentke T.M., Schmidt W.J. Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit Rev Neurobiol. 14:2000;131-142.
37. Vezina P., Blanc G., Glowinski J., Tassin J.P. Opposed behavioural outputs of increased dopamine transmission in prefrontocortical and subcortical areas a role for the cortical D-1 dopamine receptor . Eur J Neurosci. 3:1991;1001-1007.
38. Waddington J.L., Daly S.A., Downes R.P., Deveney A.M., McCauley P.G., O'Boyle K.M. Behavioural pharmacology of 'D-1-like' dopamine receptors further subtyping, new pharmacological probes and interactions with 'D-2-like' receptors . Prog Neuropsychopharmacol Biol Psychiatry. 19:1995;811-831.
39. Winer B.J. Statistical principles in experimental design. 1971;McGraw-Hill, New York.
40. Wirtshafter D. D1 dopamine receptors mediate neuroleptic-induced Fos expression in the islands of Calleja. Synapse. 28:1998;154-159.